We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Next Generation Immunoassay Analyzer Boasts Industry’s Highest Throughput per Footprint

By LabMedica International staff writers
Posted on 16 May 2023
Print article
Image: The DxI 9000 Access immunoassay analyzer enables elite laboratory performance with no daily maintenance (Photo courtesy of Beckman Coulter)
Image: The DxI 9000 Access immunoassay analyzer enables elite laboratory performance with no daily maintenance (Photo courtesy of Beckman Coulter)

Clinical laboratories worldwide are running more tests than at any time in history, creating the need for a platform that can address today's laboratories' requirements for speed, accuracy, and reliability. Now, an innovation-packed immunoassay analyzer will enable labs across the globe to improve their throughput rates and turnaround times with unparalleled precision.

Beckman Coulter (Brea, CA, USA) has introduced the DxI 9000 Access immunoassay analyzer, the most efficient immunoassay analyzer per footprint capable of conducting up to 215 tests per hour per square meter (tests/hr/m2). The DxI 9000 Access incorporates innovations designed to address current demands for speed, dependability, reproducibility, quality, and menu expansion. These advancements improve assay performance and lab productivity, incorporating new technologies for analyte processing and detection, precision sensors, smart algorithms, and real-time system monitoring.

The DxI 9000 Access stands alone as the only immunoassay analyzer that requires no daily maintenance. Its ZeroDaily Maintenance feature emphasizes the embedded innovations that enhance the analyzer's uptime performance. Beta users have endorsed ZeroDaily Maintenance for transforming their workday by eliminating daily maintenance needs, consequently reducing annual maintenance routines by up to 96%. The DxI 9000 Access also incorporates PrecisionVision Technology, which is unrivaled in its capacity to inspect, identify, and prevent incorrect reporting in real time. Its automated safeguards include tube identification, cap detection, tip check, sample aspiration, and delivery, residual wash volume, and substrate volume. Each check mitigates the risk of reporting inaccurate data and boosts system reliability and reproducibility.

Beckman Coulter's newly developed remote service and diagnostic solution, DxS IntelliServe, interfaces with DxI 9000 Analyzers to track data and error patterns, facilitating proactive system servicing when required. The DxS IntelliServe solution also identifies service experts to resolve issues via real-time monitoring, remote operation, and troubleshooting, thereby maximizing lab uptime and performance. Furthermore, IntelliServe's remote update features and proactive scheduling ensure systems are always utilizing the latest software, minimizing unexpected workflow disruptions or downtime.

Beckman Coulter's Access NT-proBNP assay measures the concentration of N-terminal pro B-type natriuretic peptide originating from a person's heart. Elevated levels of natriuretic peptides can signal heart failure. Access NT-proBNP provides swift results in under 11 minutes and enhances accuracy in diagnosing heart failure with age-based cutoffs and disease-specific comorbidity data for superior test result interpretation. This platform has been independently validated to perform at the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) optimal level, the highest level of EFLM performance evaluation. Simultaneously, the new Lumi-Phos PRO Substrate has demonstrated the potential to develop increasingly sensitive and clinically relevant assays, ensuring the system's readiness to meet future healthcare requirements. The DxI 9000 Access Immunoassay Analyzer is currently available in most countries worldwide.

“The DxI 9000 Access Immunoassay Analyzer sets new expectations for immunoassay testing operational performance and ability to develop and sustain improved assay sensitivity to meet tomorrow's analytical needs,” said Julie Sawyer Montgomery, President, Beckman Coulter Diagnostics. “Those in the laboratory will treasure ZeroDaily Maintenance to save them time, PrecisionVision Technology to safeguard against flawed data reports, and IntelliServe to maximize system uptime. At the same time, clinical researchers are excited about the DxI 9000 Analyzer's capability to keep pace with increasingly sensitive testing requirements as healthcare providers and pharmaceutical companies take aim at ever more challenging diseases. An inspiring feat of technology, the DxI 9000 Analyzer is a comprehensive healthcare innovation.”

Related Links:
Beckman Coulter 

Flocked Swab
HydraFlock and PurFlock Ultra
Platinum Supplier
Automatic Nucleic Acid Extractor
GeneFlex 16n
Semi-Automatic Biochemistry Analyzer
Automated Chemistry Analyzer
TC-Matrix 600

Print article


Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more


view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more


view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more


view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more


view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more


view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more


view channel
Image: The global hemostasis diagnostics market is expected to reach USD 3.95 billion by 2025 (Photo courtesy of Freepik)

Global Hemostasis Diagnostics Market Driven by Increase in Invasive Surgical Procedures

Injury or surgery naturally creates bleeding in living beings, which must be stopped to prevent excessive blood loss. The human body implements a protective mechanism known as hemostasis to stop excessive bleeding.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.